BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) have been given a consensus rating of “Moderate Buy” by the fifteen ratings firms that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $390.00.

A number of analysts recently weighed in on the stock. Royal Bank Of Canada upped their price target on shares of BeOne Medicines from $425.00 to $436.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 2nd. Jefferies Financial Group cut shares of BeOne Medicines from a “buy” rating to a “hold” rating and decreased their price target for the stock from $420.00 to $290.00 in a research report on Monday, March 16th. Morgan Stanley reaffirmed an “overweight” rating and set a $395.00 price target on shares of BeOne Medicines in a research report on Thursday, May 7th. Truist Financial reissued a “buy” rating and set a $413.00 price target (up from $411.00) on shares of BeOne Medicines in a research report on Thursday, May 7th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of BeOne Medicines in a research report on Monday, April 20th.

Insider Activity

In related news, insider Lai Wang sold 1,367 shares of the business’s stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $269.38, for a total transaction of $368,242.46. Following the transaction, the insider directly owned 40 shares of the company’s stock, valued at approximately $10,775.20. The trade was a 97.16% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Aaron Rosenberg sold 631 shares of BeOne Medicines stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $257.74, for a total transaction of $162,633.94. Following the sale, the chief financial officer directly owned 397,891 shares in the company, valued at $102,552,426.34. This trade represents a 0.16% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 21,466 shares of company stock worth $5,768,875 in the last ninety days. 6.19% of the stock is currently owned by company insiders.

Institutional Trading of BeOne Medicines

Several institutional investors and hedge funds have recently bought and sold shares of the company. Capital International Investors increased its stake in BeOne Medicines by 1.3% during the fourth quarter. Capital International Investors now owns 5,113,866 shares of the company’s stock valued at $1,553,909,000 after purchasing an additional 67,808 shares during the last quarter. Siren L.L.C. increased its stake in BeOne Medicines by 1.4% during the fourth quarter. Siren L.L.C. now owns 500,000 shares of the company’s stock valued at $151,905,000 after purchasing an additional 7,010 shares during the last quarter. Morgan Stanley increased its stake in BeOne Medicines by 23.9% during the fourth quarter. Morgan Stanley now owns 437,661 shares of the company’s stock valued at $132,966,000 after purchasing an additional 84,367 shares during the last quarter. Bank of America Corp DE increased its stake in BeOne Medicines by 7.0% during the first quarter. Bank of America Corp DE now owns 405,273 shares of the company’s stock valued at $120,354,000 after purchasing an additional 26,441 shares during the last quarter. Finally, Candriam S.C.A. increased its stake in BeOne Medicines by 31.7% during the first quarter. Candriam S.C.A. now owns 259,731 shares of the company’s stock valued at $77,132,000 after purchasing an additional 62,470 shares during the last quarter. Institutional investors and hedge funds own 48.55% of the company’s stock.

BeOne Medicines Trading Up 0.6%

Shares of ONC opened at $271.80 on Tuesday. The company has a current ratio of 3.64, a quick ratio of 3.27 and a debt-to-equity ratio of 0.20. The firm has a market capitalization of $29.82 billion, a P/E ratio of 60.81 and a beta of 0.49. The stock’s fifty day simple moving average is $294.48 and its 200 day simple moving average is $311.57. BeOne Medicines has a twelve month low of $239.25 and a twelve month high of $385.22.

BeOne Medicines (NASDAQ:ONC) last posted its earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share (EPS) for the quarter. The firm had revenue of $1.51 billion during the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. On average, equities research analysts forecast that BeOne Medicines will post 6.14 earnings per share for the current year.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.